Jeffrey M. Spier, MD

Jeffrey M. Spier, MD, and Travis Mendel, MD, discuss the use of Advanced Prostate Cancer (APC) Pathways within large urology group practices. Dr. Spier begins by reviewing the impact of oral options and other advances in treatment collaboration between APC patients and their physicians which led to the formation of large urology group practices.

Dr. Spier then discusses the factors which contribute to the success of large urology groups in treating patients with APC, with an emphasis on improved quality of care. He highlights the importance of combining real-world clinical intelligence with a multidisciplinary approach for continuous improvement in the quality of care received by patients.

Dr. Mendel takes over from Dr. Spier by explaining the differences between clinical guidelines and clinical pathways. He presents examples of treatment pathways for various stages of APC, with a focus on the impact of PSMA-PET.

Dr. Mendel concludes by discussing the potential use of these pathways in creating better AI treatment aids for physicians. Dr. Spier ends the presentation with an emphasis on the positive impact of a multidisciplinary team.